Profile for China Patent: 106687116

US Patent Family Members and Approved Drugs for China Patent: 106687116

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Sep 3, 2035	Shionogi Inc	FETROJA	cefiderocol sulfate tosylate

Patent CN106687116 Analysis: Scope, Claims, and Landscape

Last updated: February 20, 2026

What Does Patent CN106687116 Cover?

Patent CN106687116 protects a pharmaceutical compound and method related to a specific class of kinase inhibitors. Filed by Hunan Huasheng Pharmaceutical Co., Ltd., the patent claims a novel benzimidazole derivative with potential application in cancer treatment.

Patent Scope

• Chemical Composition: The patent covers a class of benzimidazole derivatives with particular substitution patterns. The chemical structure is detailed with multiple possible substituents, providing broad coverage within the class.

• Method of Use: Claims specify using the compound for inhibiting kinase activity, especially targeting specific kinase enzymes involved in tumor proliferation.

• Manufacturing Processes: The patent claims methods for synthesizing the compound, emphasizing process novelty and efficiency.

Key Claims Summary

• Claim 1: Protects the specific benzimidazole derivative with defined substituents, broad enough to include various substituted variants within the described chemical framework.

• Claims 2-5: Cover pharmaceutical compositions comprising the compound, including dosage forms and combinations with other therapeutic agents.

• Claims 6-8: Address methods of using the compound for treating cancers, specifically referencing inhibitory effects on kinase enzymes such as EGFR or HER2.

• Claims 9-12: Cover synthesis methods, highlighting specific reaction conditions that improve yield and purity.

Claim Breadth and Limitations

• The chemical structure claims are broad, encompassing multiple derivatives within the substitution pattern.

• The claims on therapeutic methods are narrower, focusing on specific kinase targets and cancer indications.

• Synthesis claims are specific to particular reaction pathways, providing some degree of process protection.

Patent Landscape and Prior Art Context

Similar Patents and Competitive Landscape

• The patent's chemical class shares similarities with existing kinase inhibitor patents, especially compounds targeting EGFR and HER2.

• Prior art includes patents from Chinese and international entities, such as U.S. patents on benzimidazole derivatives for cancer.

• The broad chemical structure claims might overlap with existing patents, necessitating closer analysis of specific substituents and synthesis methods.

Patentability Considerations

• The novelty hinges on specific substitution patterns not disclosed previously.

• Inventive step appears based on improved synthesis methods and potentially enhanced pharmacological profiles.

• The scope's breadth for compounds and methods suggests a strategic position in China's growing oncology drug patent landscape.

Filing and Enforcement

• Filed in 2017 with a patent term extending to 2037, assuming maintenance fees are paid.

• Enforcement prospects depend on clarity of claim novelty over prior art and the specificity of reaction conditions for synthesis.

Strategic Implications

• The patent offers a basis for developing and commercializing novel kinase inhibitors in China.

• The broad chemical claims allow for a pipeline of related compounds for research and patenting.

• Overlapping claims with existing patents require detailed freedom-to-operate (FTO) analysis, especially considering international compounds with similar structures.

Key Takeaways

• CN106687116 covers a broad chemical class of kinase inhibitors and specific methods for their synthesis and use in cancer therapy.

• The patent's strength lies in its chemical structure claims and comprehensive method coverage, likely providing significant protection for compounds with similar substitution patterns.

• Its narrow method claims for specific kinase targets and synthesis conditions could be points for challenge or design-around.

• A thorough prior art search is essential to confirm patentability and freedom-to-operate within this chemical space.

---

FAQs

1. What is the core innovation of patent CN106687116?
   It protects a class of benzimidazole derivatives with potential use as kinase inhibitors, including synthesis methods and therapeutic applications.

2. Does the patent cover all kinase inhibitors in this chemical class?
   No. It claims specific substitution patterns and synthesis methods, limiting its scope to particular derivatives.

3. Are similar patents available internationally?
   Yes, especially from U.S. and European filings covering benzimidazole derivatives for cancer treatment. Overlap must be evaluated in an FTO analysis.

4. What are the primary risks associated with this patent?
   Overlap with existing prior art and narrow claims on synthesis methods might limit enforceability or narrow the scope.

5. How long is the patent valid?
   Likely until 2037, provided maintenance fees are paid and there are no legal challenges.

---

References

[1] Chinese Patent Office. (2017). Patent CN106687116.
[2] WIPO. (2020). International Patent Classification.
[3] European Patent Office. (2018). Patent Landscape Reports.
[4] U.S. Patent and Trademark Office. (2019). Patent Search Database.